Clinical Trial Update: A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the antiangiogenic agent anlotinib in patients with recurrent/metastatic head and neck adenocarcinomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Head and Neck Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Carcinoma, Adenocarcinoma | Phase 2 | Status: UNKNOWN